Author Archives: Warren Woessner

In re: Board of Trustees of Stanford: “Big Data” Personalized Medicine is an Abstract Idea

Posted on March 12, 2021 by Warren Woessner

In re: Board of Trustees of the Leland Stanford Junior University, Appeal no. 2020-1012 (Federal Circuit, March 11, 2021) a three judge panel of Prost, Lurie and Reyna affirmed the ruling by the Board of Appeals that the claims of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Announcing “Mueller on Patent Law” from Fastcase

Posted on March 3, 2021 by Warren Woessner

Guest post from Chisum Patent Academy: The Chisum Patent Academy is pleased to announce the January 2021 publication of the two-volume practitioner treatise, Mueller on Patent Law, in print and electronic formats. The treatise is authored by our co-founder, Janice … Continue reading →

Posted in Miscellaneous | Tagged , | Leave a comment

Upcoming AUTM Webinar Examines Avoiding the Trap of Inequitable Conduct

Posted on March 1, 2021 by Warren Woessner

On March 4, an AUTM webinar will discuss, “Inequitable Conduct: How to Protect Your Patents from this Unenforceability Trap”. This presentation will take place from 12 p.m. to 1:30 p.m. Eastern time this Thursday. Panelists will include David Hricik of … Continue reading →

Posted in Inequitable Conduct/Rule 56, Webinar | Tagged , | Leave a comment

Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear

Posted on February 13, 2021 by Warren Woessner

While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading →

Posted in Enablement | Tagged , , | Leave a comment